Recruiting

Empagliflozin for Left Atrial Function in Heart Failure Risk Patients

Study Aim

This study aims to evaluate how Empagliflozin affects the function of the left atrium in people at risk of heart failure over nine months.

What is being tested

empagliflozin

+ Placebo tablet

Drug

Who is being recruted

Cardiovascular Diseases

+ Hypertension

+ Vascular Diseases

Over 60 Years

+21 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledEarly Phase 1

Interventional

Study Start: December 2024

See protocol details

Summary

Principal SponsorUniversity of Minnesota

Study ContactJulie Dicken, RN

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: December 12, 2024

Actual date on which the first participant was enrolled.

This study focuses on the medication empagliflozin, a type of drug known as a sodium-glucose cotransporter 2 inhibitor, which is initially used to treat type 2 diabetes. Researchers are exploring its potential benefits for people at risk of heart failure, particularly its impact on the function of the left atrium, a part of the heart. The study targets adults who may develop heart failure, aiming to discover if this medication can improve heart function and potentially prevent heart-related issues in these individuals. Understanding how empagliflozin affects the heart could lead to better preventive treatments for those at risk of heart failure. Participants in the study are randomly assigned to receive either a daily 10mg empagliflozin tablet or a placebo, which is a pill without active medication, to compare the effects. The study is designed so neither the participants nor the researchers know who is receiving the actual medication, ensuring unbiased results. The main focus is on monitoring the function of the left atrium to see if there are noticeable improvements. While risks are not detailed, such studies typically monitor for any side effects from the medication. This research could provide valuable insights into new ways to prevent heart complications in vulnerable populations.

Official TitleEffect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

NCT06507657

Principal SponsorUniversity of Minnesota

Study ContactJulie Dicken, RN

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

80 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesHypertensionVascular Diseases

Criteria

4 inclusion criteria required to participate

Age >60 years of age

Clinical diagnosis of hypertension

Body mass index ≥30kg/m2

We will screen for participants with an echocardiogram within 60 days of the baseline visit

17 exclusion criteria prevent from participating

Female participants who are pregnant, lactating, or of child bearing potential

History of type 1 or type 2 diabetes mellitus by medical history or hemoglobin A1c >7.0% at Visit 1

Clinical diagnosis of HFpEF or HFrEF by participant self-report or documented in the electronic health record

Any LVEF measure of ≤40% on past echocardiogram

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

Group II

Placebo

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

University of Minnesota

Minneapolis, United StatesOpen University of Minnesota in Google Maps

Recruiting

One Study Center